BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38623942)

  • 1. The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults.
    Perumpail BJ; Manikat R; Wijarnpreecha K; Cholankeril G; Ahmed A; Kim D
    J Pediatr Gastroenterol Nutr; 2024 Apr; ():. PubMed ID: 38623942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature.
    Ma N; Bansal M; Chu J; Branch AD
    J Pediatr Gastroenterol Nutr; 2024 May; ():. PubMed ID: 38693784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
    Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
    Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease.
    Zhang W; Song WJ; Chen W; Pan Z; Zhang J; Fan L; Li J
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):802-810. PubMed ID: 38526946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between food insecurity and metabolic dysfunction-associated steatotic liver disease/significant fibrosis measured by fibroscan.
    Kim D; Perumpail BJ; Cholankeril G; Ahmed A
    Eur J Nutr; 2024 Apr; 63(3):995-1001. PubMed ID: 38260997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of an Eight Week Very Low-Calorie Ketogenic Diet (VLCKD) on White Blood Cell and Platelet Counts in Relation to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Subjects with Overweight and Obesity.
    De Nucci S; Bonfiglio C; Donvito R; Di Chito M; Cerabino N; Rinaldi R; Sila A; Shahini E; Giannuzzi V; Pesole PL; Coletta S; Lanzilotta E; Piazzolla G; Cozzolongo R; Giannelli G; De Pergola G
    Nutrients; 2023 Oct; 15(20):. PubMed ID: 37892542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and predictive features of metabolic dysfunction-associated steatotic liver disease in type 1 diabetes.
    Fuhri Snethlage CM; Meijnikman AS; Mak AL; Rampanelli E; Voermans B; Callender CAK; de Groen P; Roep BO; van Raalte DH; Knop FK; Holleboom AG; Nieuwdorp M; Hanssen NMJ
    Eur J Endocrinol; 2024 May; 190(5):391-400. PubMed ID: 38679966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Steatotic Liver Disease Among US Adults with Rheumatoid Arthritis.
    Vassilopoulos A; Kalligeros M; Vassilopoulos S; Shehadeh F; Benitez G; Kaczynski M; Lazaridou I; Promrat K; Wands JR; Mylonakis E
    Dig Dis Sci; 2024 Mar; 69(3):989-1003. PubMed ID: 38183561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Risk Factors of MASLD and Liver Fibrosis amongst the Penitentiary Population in Catalonia: The PRISONAFLD Study.
    Rivera-Esteban J; Jiménez-Masip A; Muñoz-Martínez S; Augustin S; Guerrero RA; Gabriel-Medina P; Ferrer-Costa R; Rodríguez-Frías F; Turu E; Marco A; Pericàs JM; On Behalf Of The Prisonafld Study Group Collaborators
    J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary macro and micronutrients associated with MASLD: Analysis of a national US cohort database.
    Nemer M; Osman F; Said A
    Ann Hepatol; 2024; 29(3):101491. PubMed ID: 38412922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of continuous controlled attenuation parameter and liver stiffness measurement by the novel SmartExam in metabolic dysfunction-associated steatotic liver disease.
    Song SJ; Nogami A; Liang LY; Yoneda M; Leung HHW; Nakajima A; Lai JCT; Wong GLH; Shu SST; Wong VWS; Yip TCF
    Liver Int; 2024 May; 44(5):1167-1175. PubMed ID: 38353063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus.
    Mantovani A; Morieri ML; Aldigeri R; Palmisano L; Masulli M; Bonomo K; Baroni MG; Cossu E; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Cas AD; de Kreutzenberg SV; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101497. PubMed ID: 37992857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomic Phenotype of Hepatic Steatosis and Fibrosis in Mexican Children Living with Obesity.
    Garibay-Nieto N; Pedraza-Escudero K; Omaña-Guzmán I; Garcés-Hernández MJ; Villanueva-Ortega E; Flores-Torres M; Pérez-Hernández JL; León-Hernández M; Laresgoiti-Servitje E; Palacios-González B; López-Alvarenga JC; Lisker-Melman M; Vadillo-Ortega F
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893503
    [No Abstract]   [Full Text] [Related]  

  • 16. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.
    Ochoa-Allemant P; Marrero JA; Serper M
    Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38051551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient Elastography Measures of Hepatic Steatosis and Fibrosis Are Associated With Body Composition Among US Adolescents.
    Unalp-Arida A; Ruhl CE
    J Pediatr Gastroenterol Nutr; 2022 Oct; 75(4):497-505. PubMed ID: 35758468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of weight gain and metabolic dysfunction-associated steatotic liver disease on liver fibrosis progression and regression in people with HIV.
    Guaraldi G; Milic J; Renzetti S; Motta F; Cinque F; Bischoff J; Desilani A; Conti J; Medioli F; Del Monte M; Kablawi D; Elgretli W; Calza S; Mussini C; Rockstroh JK; Sebastiani G
    AIDS; 2024 Apr; ():. PubMed ID: 38597416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017-2018 National Health and Nutrition Examination Survey.
    Ciardullo S; Monti T; Perseghin G
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):384-390.e1. PubMed ID: 32623006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, trends, and characteristics of metabolic dysfunction-associated steatotic liver disease among the US population aged 12-79 years.
    Shen TH; Wu CH; Lee YW; Chang CC
    Eur J Gastroenterol Hepatol; 2024 May; 36(5):636-645. PubMed ID: 38477858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.